EXAS
BEARISH
$104.91
Live
Exact Sciences Corp · NASDAQ
Target $106.3
(+1.3%)
$38.81
52W Range
$104.98
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 09, 2026
Market cap
$20.03B
P/E
N/A
ROE
-8.7%
Profit margin
-6.4%
Debt/Equity
1.06
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
EXAS shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.
Key Strengths
Strong revenue growth of 23.1%
Key Risks
Low profit margin of -6.4%
Weak financial trend (Piotroski F-Score: 2/9)
Weak ROE of -8.7%
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
35
Weak
50
65
30
30
0
AI Verdict
EXAS shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.
Key drivers: Strong revenue growth of 23.1%, Low profit margin of -6.4%, Weak financial trend (Piotroski F-Score: 2/9)
Confidence
35%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
65/100
Rule-based growth outlook.
Positives
- Revenue growth running at 23.1%.
Watchpoints
No urgent risks highlighted.
Past
30/100
Historical performance + price trend: Shares moved -16.4% over 5Y and +122.8% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- ROE only -8.7%.
- Thin profit margins.
Health
30/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$104.91
Analyst Target
$106.3
Upside/Downside
+1.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for EXAS and closest competitors.
Updated 2026-03-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
EXAS
Exact Sciences Corp
Primary
|
-16.4% | +58.3% | +122.8% | +95.9% | +1.4% | +1.0% |
|
MRNA
Moderna, Inc.
Peer
|
-61.7% | -66.9% | +79.2% | +96.7% | -3.9% | -1.1% |
|
ILMN
Illumina, Inc.
Peer
|
-67.1% | -45.5% | +55.4% | +29.8% | -7.2% | -2.2% |
|
INCY
Incyte Corporation
Peer
|
+13.4% | +30.2% | +55.4% | +11.0% | -5.9% | +3.9% |
|
HUM
Humana Inc.
Peer
|
-54.8% | -63.9% | -31.8% | -27.3% | -4.6% | +2.6% |
EXA
Exact Sciences Corp
Primary
5Y
-16.4%
3Y
+58.3%
1Y
+122.8%
6M
+95.9%
1M
+1.4%
1W
+1.0%
MRN
Moderna, Inc.
Peer
5Y
-61.7%
3Y
-66.9%
1Y
+79.2%
6M
+96.7%
1M
-3.9%
1W
-1.1%
ILM
Illumina, Inc.
Peer
5Y
-67.1%
3Y
-45.5%
1Y
+55.4%
6M
+29.8%
1M
-7.2%
1W
-2.2%
INC
Incyte Corporation
Peer
5Y
+13.4%
3Y
+30.2%
1Y
+55.4%
6M
+11.0%
1M
-5.9%
1W
+3.9%
HUM
Humana Inc.
Peer
5Y
-54.8%
3Y
-63.9%
1Y
-31.8%
6M
-27.3%
1M
-4.6%
1W
+2.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
55.22
PEG Ratio
N/A
P/B Ratio
8.34
P/S Ratio
6.17
EV/Revenue
6.65
EV/EBITDA
302.23
Market Cap
$20.03B
Profitability
Profit margins and return metrics
Profit Margin
-6.4%
Operating Margin
-9.28%
Gross Margin
69.69%
ROE
-8.66%
ROA
-1.59%
Growth
Revenue and earnings growth rates
Revenue Growth
+23.1%
Earnings Growth
N/A
Q/Q Revenue Growth
+23.12%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.06
Moderate
Current Ratio
2.43
Strong
Quick Ratio
1.97
Excellent
Cash/Share
$5.05
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.9B
Gross Margin
70.1%
Op. Margin
-9.4%
Net Margin
-9.8%
Total Assets
$5.9B
Liabilities
$3.5B
Equity
$2.4B
Debt/Equity
1.44x
Operating CF
$0.2B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
79%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-13
$-0.21
-378.3% surprise
2025-11-03
$0.24
+49.5% surprise
2025-08-06
$0.1
+84.9% surprise
2025-05-01
$-0.54
-41.6% surprise
Healthcare Sector Comparison
Comparing EXAS against 189 companies in the Healthcare sector
(17 bullish, 63 neutral, 109 bearish)
Return on Equity (ROE)
-8.66%
This Stock
vs
-44.08%
Sector Avg
-80.4%
(Below Avg)
Profit Margin
-6.4%
This Stock
vs
-19.57%
Sector Avg
-67.3%
(Weaker)
Debt to Equity
1.06
This Stock
vs
5.1
Sector Avg
-79.3%
(Less Debt)
Revenue Growth
23.1%
This Stock
vs
108.17%
Sector Avg
-78.6%
(Slower)
Current Ratio
2.43
This Stock
vs
3.39
Sector Avg
-28.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
EXAS
Exact Sciences Corp
|
BEARISH | $20.03B | - | -8.7% | -6.4% | $104.91 | |
|
MRNA
Moderna, Inc.
|
BEARISH | $20.15B | - | -28.9% | -145.2% | $50.8 | Compare |
|
ILMN
Illumina, Inc.
|
NEUTRAL | $18.85B | 22.62 | 33.4% | 19.6% | $123.26 | Compare |
|
INCY
Incyte Corporation
|
BULLISH | $18.73B | 15.3 | 29.9% | 25.0% | $94.12 | Compare |
|
HUM
Humana Inc.
|
BEARISH | $21.45B | 18.06 | 7.0% | 0.9% | $177.86 | Compare |
EXAS
Exact Sciences Corp
BEARISH
Mkt Cap
$20.0B
P/E
-
ROE
-8.7%
Price
$104.91
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-23 | CONDELLA SARAH K | Officer | Stock Award | 60,389 | - |
| 2026-03-23 | BARANICK BRIAN | Officer | Stock Award | 33,321 | - |
| 2026-03-23 | BLOOMER AARON | Chief Financial Officer | Stock Award | 89,911 | - |
| 2026-03-23 | ORVILLE JACOB A | Officer | Stock Award | 53,323 | - |
| 2026-03-23 | CONROY KEVIN T | Chief Executive Officer | Stock Award | 119,312 | - |
| 2026-02-27 | CONROY KEVIN T | Chief Executive Officer | Stock Award | 68,097 | - |
| 2026-02-27 | CONDELLA SARAH K | Officer | Option Exercise | 3,900 | $19,617 |
| 2026-02-25 | CONROY KEVIN T | Chief Executive Officer | Stock Award | 13,181 | - |
| 2025-12-24 | BARANICK BRIAN | Officer | Stock Award | 92,523 | - |
| 2025-12-23 | ORVILLE JACOB A | Officer | Stock Award | 73,080 | - |
| 2025-12-23 | CONDELLA SARAH K | Officer | Stock Award | 42,018 | - |
| 2025-12-23 | HERRIOTT JAMES | General Counsel | Stock Award | 72,320 | - |
| 2025-12-23 | ORVILLE JACOB A | Officer | Stock Award | 72,523 | - |
| 2025-12-23 | CONROY KEVIN T | Chief Executive Officer | Stock Award | 713,931 | - |
| 2025-12-23 | CONDELLA SARAH K | Officer | Stock Award | 47,208 | - |
CONDELLA SARAH K
Officer
2026-03-23
60,389 shares
BARANICK BRIAN
Officer
2026-03-23
33,321 shares
BLOOMER AARON
Chief Financial Officer
2026-03-23
89,911 shares
ORVILLE JACOB A
Officer
2026-03-23
53,323 shares
CONROY KEVIN T
Chief Executive Officer
2026-03-23
119,312 shares
CONROY KEVIN T
Chief Executive Officer
2026-02-27
68,097 shares
CONDELLA SARAH K
Officer
2026-02-27
3,900 shares
·
$19,617
CONROY KEVIN T
Chief Executive Officer
2026-02-25
13,181 shares
BARANICK BRIAN
Officer
2025-12-24
92,523 shares
ORVILLE JACOB A
Officer
2025-12-23
73,080 shares
CONDELLA SARAH K
Officer
2025-12-23
42,018 shares
HERRIOTT JAMES
General Counsel
2025-12-23
72,320 shares
ORVILLE JACOB A
Officer
2025-12-23
72,523 shares
CONROY KEVIN T
Chief Executive Officer
2025-12-23
713,931 shares
CONDELLA SARAH K
Officer
2025-12-23
47,208 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
10 analysts
Mizuho
2026-01-20
Outperform
Neutral
Evercore ISI Group
2026-01-05
Outperform
In-Line
Stifel
2025-11-28
Buy
Hold
Canaccord Genuity
2025-11-25
Buy
Hold
Benchmark
2025-11-24
Buy
Hold
Jefferies
2025-11-24
Buy
Hold
Wells Fargo
2025-11-21
Overweight
Equal-Weight
William Blair
2025-11-21
Outperform
Market Perform
Guggenheim
2025-11-21
Buy
Neutral
Barclays
2025-11-21
Overweight
Equal-Weight
Past News Coverage
Recent headlines mentioning EXAS from our newsroom.
Newest → oldest
No matching news yet.